


PHARMACEUTICAL 2021

RIGEL PHARMACEUTICALS INC Rank 155 of 409







PHARMACEUTICAL 2021

RIGEL PHARMACEUTICALS INC Rank 155 of 409



The relative strengths and weaknesses of RIGEL PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RIGEL PHARMACEUTICALS INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 439% points. The greatest weakness of RIGEL PHARMACEUTICALS INC is the variable Assets, Current, reducing the Economic Capital Ratio by 128% points.

The company's Economic Capital Ratio, given in the ranking table, is -57%, being 298% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	88,983
Cost of Goods Sold	895
Intangible Assets	0
Liabilities, Current	40,841
Liabilities, Non-Current	0
Other Assets	18,719
Other Compr. Net Income	-798
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Property and Equipment	2,676
Research and Development	60,101
Revenues	108,621
Selling, General and Administrative Expense	76,598

Output Variable	Value in 1000 USD
Assets	110,378
Liabilities	40,841
Expenses	137,594
Stockholders Equity	69,537
Net Income	-28,973
Comprehensive Net Income	-29,372
Economic Capital Ratio	-57%